Physician profile
Om Dutt Sharma
NPI 1497798342
$2,292.84
in general payments reported to CMS, 2019-2025
20 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.46 · 2020: $85.21 · 2021: $245 · 2022: $167 · 2023: $531 · 2024: $482 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731 · Education: $24.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.11 |
| Education | $24.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $961.17 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $519.05 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $191.25 | 2022-2025 | |
| Boston Scientific Corporation | $130.07 | 2023-2024 | Watchman Access System, Watchman Flx |
| Exact Sciences Corporation | $85.95 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $67.13 | 2019-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $42.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.82 | 2024-2025 | |
| Insmed, INC. | $37.39 | 2025 | Brinsupri, Arikayce |
| Amarin Pharma, INC. | $33.21 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.50 | 2025 | Jardiance |
| Sun Pharmaceutical Industries INC. | $26.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.64 | 2024 | Voquezna |
| Amgen INC. | $19.14 | 2023 | Otezla, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.80 | 2024 | Xifaxan |
| Glaxosmithkline, LLC. | $14.37 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.10 | 2021 | |
| Abbott Laboratories | $13.44 | 2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $12.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Om Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.